Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Accutar Biotechnology synthesizes new PROTACs for cancer

Oct. 30, 2020

Qilu Regor Therapeutics identifies tyrosine kinase inhibitors

Oct. 30, 2020

Zhuhai Yufan Biotechnologies patents CDK inhibitors

Oct. 30, 2020

Lynk Pharmaceuticals discloses new JAK inhibitors

Oct. 30, 2020

Six months of therapy completed in low-dose cohort of phase I/II brain cancer study of NOX-A12

Oct. 30, 2020

Scandion Oncology initiates phase Ib pancreatic cancer study of SCO-101

Oct. 29, 2020

NMBS-2: a selective and potent HPK1 inhibitor for enhancing antitumor immunity

Oct. 29, 2020

AUR-102: a potent and selective CDK7 inhibitor for cancer treatment

Oct. 29, 2020

Recruitment completed in phase III FORTRESS study of balixafortide

Oct. 29, 2020

Australian regulatory authorities approve phase I study of APL-1501

Oct. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...